Traditionally, breast cancer (BC) is divided into different immunohistochemically (IHC)-defined subtypes, according to the expression of hormone receptors and overexpression/amplification of human epidermal growth factor receptor 2 (HER2), with crucial therapeutic implications. In the last few years, the definition of different BC molecular subgroups within the IHC-defined subtypes and the identification of the important role that molecular heterogeneity can play in tumor progression and treatment resistance have inspired the search for personalized therapeutic approaches. In this scenario, translational research represents a key strategy to apply knowledge from cancer biology to the clinical setting, through the study of all the tumors "omics", including genomics, transcriptomics, proteomics, epigenomics, and metabolomics. Importantly, the introduction of new high-throughput technologies, such as next generation sequencing (NGS) for the study of cancer genome and transcriptome, greatly amplifies the potential and the applications of translational research in the oncology field. Moreover, the introduction of new experimental approaches, such as liquid biopsy, as well as new-concept clinical trials, such as biomarker-driven adaptive studies, may represent a turning point for BC translational research. It is likely that translational research will have in the near future a significant impact in BC care,, especially by giving us the possibility to dissect the complexity of tumor cell biology and develop new personalized treatment strategies.

The Impact of Translational Research in Breast Cancer Care: Can We Improve the Therapeutic Scenario? / Perri, Francesco; Buono, Giuseppe; Schettini, Francesco; Arpino, Grazia; Bianco, Roberto; Criscitiello, Carmen; De Placido, Sabino; Giuliano, Mario. - In: ANTI-CANCER AGENTS IN MEDICINAL CHEMISTRY. - ISSN 1875-5992. - (2017). [10.2174/1871520617666171103105247]

The Impact of Translational Research in Breast Cancer Care: Can We Improve the Therapeutic Scenario?

PERRI, FRANCESCO;BUONO, GIUSEPPE;Schettini, Francesco;Arpino, Grazia
Conceptualization
;
Bianco, Roberto
Conceptualization
;
De Placido, Sabino
Conceptualization
;
Giuliano, Mario
Conceptualization
2017

Abstract

Traditionally, breast cancer (BC) is divided into different immunohistochemically (IHC)-defined subtypes, according to the expression of hormone receptors and overexpression/amplification of human epidermal growth factor receptor 2 (HER2), with crucial therapeutic implications. In the last few years, the definition of different BC molecular subgroups within the IHC-defined subtypes and the identification of the important role that molecular heterogeneity can play in tumor progression and treatment resistance have inspired the search for personalized therapeutic approaches. In this scenario, translational research represents a key strategy to apply knowledge from cancer biology to the clinical setting, through the study of all the tumors "omics", including genomics, transcriptomics, proteomics, epigenomics, and metabolomics. Importantly, the introduction of new high-throughput technologies, such as next generation sequencing (NGS) for the study of cancer genome and transcriptome, greatly amplifies the potential and the applications of translational research in the oncology field. Moreover, the introduction of new experimental approaches, such as liquid biopsy, as well as new-concept clinical trials, such as biomarker-driven adaptive studies, may represent a turning point for BC translational research. It is likely that translational research will have in the near future a significant impact in BC care,, especially by giving us the possibility to dissect the complexity of tumor cell biology and develop new personalized treatment strategies.
2017
The Impact of Translational Research in Breast Cancer Care: Can We Improve the Therapeutic Scenario? / Perri, Francesco; Buono, Giuseppe; Schettini, Francesco; Arpino, Grazia; Bianco, Roberto; Criscitiello, Carmen; De Placido, Sabino; Giuliano, Mario. - In: ANTI-CANCER AGENTS IN MEDICINAL CHEMISTRY. - ISSN 1875-5992. - (2017). [10.2174/1871520617666171103105247]
File in questo prodotto:
Non ci sono file associati a questo prodotto.

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11588/694239
Citazioni
  • ???jsp.display-item.citation.pmc??? ND
  • Scopus 3
  • ???jsp.display-item.citation.isi??? 3
social impact